Disclosures for "Timing and Frequency of Onset Symptoms in Friedreich Ataxia Based on Real-world Medical Claims Data"
-
Dr. Khemani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cala Trio. Dr. Khemani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Khemani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine.
-
Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. Dr. Nayar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.
-
Boyang Bian has received personal compensation for serving as an employee of Biogen. Boyang Bian has stock in Biogen.
-
Mr. Gomes has received personal compensation for serving as an employee of Voxanalytica. Mr. Gomes has stock in Biogen. Mr. Gomes has stock in Roche. Mr. Gomes has stock in Novartis. Mr. Gomes has stock in Merck & Co. Inc.. Mr. Gomes has stock in Pfizer. Mr. Gomes has stock in Eli Lilly. The institution of Mr. Gomes has received research support from Biogen.
-
Dr. England has received personal compensation for serving as an employee of Biogen. Dr. England has stock in Biogen.
-
Dr. McKay has received personal compensation for serving as an employee of Biogen. Dr. McKay has stock in Biogen.
-
Dr. Wang has nothing to disclose.
-
Mrs. Avila has received personal compensation for serving as an employee of Biogen. Mrs. Avila has stock in Biogen.